Drugs / CSTC-Exo
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04389385 | May → Sep 2020 | COVID-19, pneumonia | TC Erciyes University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CSTC-Exo | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04389385 ↗ |
| Known as | COVID-19 Specific T Cell derived exosomes | “COVID-19 Specific T Cell derived exosomes (CSTC-Exo)” NCT04389385 ↗ |
| Modality | Other / unclassified | “This project is to offer a biologic agent based on T cell derived exosomes.” NCT04389385 ↗ |
| Route | Inhaled | “following targeted delivery by metered dose inhaler” NCT04389385 ↗ |